SynthesisJournal of molecular neuroscience : MN2025
A Multi-Ancestry GWAS Meta-Analysis Integrated with In-Depth Silico, Systems Biology, and Pharmacogenomics Approaches on Alzheimer's Disease Among 1,198,689 Subjects.
Synthesis in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to perform a Meta-Analysis based on GWAS data and utilized them for multi-step analyses. Final data included 1,198,682 subjects (255,810 cases and 942,872 controls) in 26 studies among 11 ethnicities. R package utilized for GWAS Meta-Analysis, a Primary Gene List (PGL), and then a Secondary Gene List (SGL) were generated. All of the in-depth silico, systems biology, and Pharmacogenomics (PGx) analyses were performed by STRING-MODEL, miRTargetLink2, NetworkAnalyst, Enrichr, and PharmGKB. The cumulative effect size in a random effects model for the risk of AD was 1.55 [95% CI: 1.41-1.71]. APOE, APP, SPI1, hsa-miR-17-5p, hsa-miR-155-5p, hsa-miR-340, hsa-miR-125b, hsa-miR-199a-3p, hsa-miR-199a-5p, and hsa-miR-1908-5p, SP1, MYC, MAX, E2F1, Valproic acid, and Tretinoin were the most significant findings. According to the Enrichment Analysis, Immune System R-HSA-168,256 (q-value = 5.85E-07) and Amyloid Fiber Formation R-HSA-977,225 (q-value = 1.57E-05) were the most significant pathways. Amyloid-Beta Binding (GO:0001540) (q-value = 3.64E-04) in molecular function were among the most significant GOs. DDAs found Alzheimer Disease (q-value = 8.72E-45) with the highest incidence. PGx approaches, uncovered 40 potential annotations, among them, two annotations of rs429358 (APOE) were both directly associated with AD. Briefly, almost all of the findings presented in this study are supported by prior reports along with new findings.
Indexed as
Identifiers
41329263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.